Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Ginkgo Bioworks (NYSE:DNA) announced a strategic transition toward commercializing autonomous laboratory hardware and cloud data services. For long-term investors, this operational evolution determines whether automated biology can build high-margin revenue streams while reducing cash burn. Three takeaways from management's call explain how this transition is unfolding. Selling autonomous lab hardware to major biopharma partners validates Ginkgo Bioworks' technology while creating high customer switching costs. Pharmaceutical giant Novo Nordisk became the first to opt into this offering. Cost cuts following restructuring efforts have improved adjusted EBITDA -- which is earnings before interest, taxes, depreciation, and amortization, a key measure of core operating profitability -- while preserving cash. Continue reading